Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03359226 · ClinicalTrials.gov registry record · NA
Transcutaneous Submandibular Gland Biopsy: Feasibility of Repeat Biopsy as a Progression Marker for Parkinson's Disease
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT03359226: Completed NA study, sponsored by Mayo Clinic.
NCT03359226 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03359226, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to perform biopsies of one of the glands that make saliva. The biopsied tissue will then be analyzed to see if it has changes that occur in Parkinson's disease. This study will determine whether it is possible to do a second biopsy a few years after a previous biopsy and determine whether there are changes in the biopsy that would allow for analysis of disease progression.
Interventions
- PROCEDURE Submandibular gland biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2018-05-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03359226
The ClinicalTrials.gov registry entry for NCT03359226 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Submandibular gland biopsy is the first listed.
NCT03359226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03359226 about?
NCT03359226 is a clinical study titled "Transcutaneous Submandibular Gland Biopsy: Feasibility of Repeat Biopsy as a Progression Marker for Parkinson's Disease". The purpose of this study is to perform biopsies of one of the glands that make saliva. The biopsied tissue will then be analyzed to see if it has changes that occur in Parkinson's disease. This study will determine whether it is possible to do a second biopsy a few years after a previous biopsy and...
What is the current status of trial NCT03359226?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2017-11-21. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT03359226?
The interventions under investigation include: Submandibular gland biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03359226?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.